Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | CA6 | P23280 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | TPMT | P51580 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24812330 | 0.93 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19TSHRCYP3A4 | |
| SCHEMBL3547706 | 0.87 | CA12 (0.71) | CYP1A2CYP2C9CYP2C19TSHRCYP3A4 | |
| SCHEMBL15174514 | 0.85 | CYP1A2 (0.51) | CYP1A2CYP2C9CYP2C19TSHRCYP3A4 | |
| SCHEMBL76834 | 0.84 | TSHR (0.73) | CYP1A2CYP2C9CYP2C19TSHRCYP3A4 | |
| SCHEMBL29399077 | 0.84 | TSHR (0.73) | CYP1A2CYP2C9CYP2C19TSHRCYP3A4 | |
| SCHEMBL27753902 | 0.84 | TSHR (0.73) | CYP1A2CYP2C9CYP2C19TSHRCYP3A4 | |
| SCHEMBL10322866 | 0.83 | KMT2A (0.45) | TSHRALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL16210218 | 0.81 | EPHX2 (0.59) | ALDH1A1KMT2AMEN1LMNAGAA | |
| SCHEMBL17407195 | 0.81 | NOTUM (0.54) | ALDH1A1KMT2AMEN1LMNASMN1; SMN2 | |
| SCHEMBL10322973 | 0.81 | APP (0.50) | KMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2024-02-29 | — | — | US | disclosed |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| WO-2022006439-A2 | COMPOUND EMBODIMENTS FOR TREATING RETINAL DEGENERATION AND METHOD EMBODIMENTS OF MAKING AND USING THE SAME | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210276999-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | HOFFMANN-LA ROCHE INC. | 2021-09-09 | — | — | US | disclosed |
| US-10851101-B2 | Compounds for treating spinal muscular atrophy | PTC THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| EP-3406252-B1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | PTC THERAPEUTICS INC (US) | 2020-05-13 | — | — | EP | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067646-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4324/4885CYP2C9 4858/4885CYP2C19 4777/4885 |
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | CYP1A2 277/4885CYP2C9 75/4885CYP2C19 34/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | CYP1A2 277/4885CYP2C9 75/4885CYP2C19 34/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CYP1A2 277/4885CYP2C9 75/4885CYP2C19 34/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | CYP1A2 3911/4885CYP2C9 3635/4885CYP2C19 4149/4885 |
| US-20210276999-A1 | COMPOUNDS FOR TREATING SPINAL MUSCULAR ATROPHY | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4324/4885CYP2C9 4858/4885CYP2C19 4777/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | CYP1A2 277/4885CYP2C9 75/4885CYP2C19 34/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | CYP1A2 277/4885CYP2C9 75/4885CYP2C19 34/4885 |
| US-10851101-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4324/4885CYP2C9 4858/4885CYP2C19 4777/4885 |
| US-11753407-B2 | Compounds for treating spinal muscular atrophy | SMN1; SMN2, CPT1B, GYS1 | CYP1A2 4094/4885CYP2C9 4799/4885CYP2C19 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.